Monoclonal antibody utilization characteristics in patients with multiple myeloma

Sikander Ailawadhi, Taimur Sher, Abdel Ghani Azzouqa, Zahara Meghji, Tania Jain, Prachi Jani, Salman Ahmed, Nancy Diehl, Vivek Roy, Vishal Shah, David Hodge, Meghna Ailawadhi, Victoria R. Alegria, Aneel Paulus, Asher Chanan-Khan, Rafael Fonseca

Research output: Contribution to journalArticle

Abstract

This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78) were more heavily pre-treated than that in published clinical trials, whereas the elotuzumab patient (n = 13) profile was similar to that published before. Infusion time was on average 2 hours less than the prescribing guidelines and premedication use varied noticeably after the initial monoclonal antibody infusion, with an overall decrease over time. We noted higher than reported haematologic adverse events, especially neutropenia and fewer non-haematologic adverse events. 91.7% infusion-related reactions were observed during the first monoclonal antibody infusion, with a subsequent decrease. All infusion-related reactions were grade 2 or less, and none of the patients discontinued treatment due to infusion-related reactions. Baseline allergy profile or laboratory tests were not associated with the likelihood of developing monoclonal antibody-related infusion-related reactions. The real-world safety profile of monoclonal antibodies showed varying adverse event patterns than those reported in previous clinical trials. The infusion-related reaction patterns were similar to previous reports. Despite changes in premedication regimens safety was maintained in succeeding infusions. Such treatment utilization data is vital to broaden our knowledge of approved therapeutic agents and maximize their benefits for patients.

Original languageEnglish (US)
Pages (from-to)859-865
Number of pages7
JournalAnti-cancer drugs
Volume30
Issue number8
DOIs
StatePublished - Sep 1 2019

Fingerprint

Multiple Myeloma
Monoclonal Antibodies
Premedication
Clinical Trials
Drug Utilization
Safety
Neutropenia
Hypersensitivity
Therapeutics
Guidelines
daratumumab
elotuzumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., ... Fonseca, R. (2019). Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anti-cancer drugs, 30(8), 859-865. https://doi.org/10.1097/CAD.0000000000000810

Monoclonal antibody utilization characteristics in patients with multiple myeloma. / Ailawadhi, Sikander; Sher, Taimur; Azzouqa, Abdel Ghani; Meghji, Zahara; Jain, Tania; Jani, Prachi; Ahmed, Salman; Diehl, Nancy; Roy, Vivek; Shah, Vishal; Hodge, David; Ailawadhi, Meghna; Alegria, Victoria R.; Paulus, Aneel; Chanan-Khan, Asher; Fonseca, Rafael.

In: Anti-cancer drugs, Vol. 30, No. 8, 01.09.2019, p. 859-865.

Research output: Contribution to journalArticle

Ailawadhi, S, Sher, T, Azzouqa, AG, Meghji, Z, Jain, T, Jani, P, Ahmed, S, Diehl, N, Roy, V, Shah, V, Hodge, D, Ailawadhi, M, Alegria, VR, Paulus, A, Chanan-Khan, A & Fonseca, R 2019, 'Monoclonal antibody utilization characteristics in patients with multiple myeloma', Anti-cancer drugs, vol. 30, no. 8, pp. 859-865. https://doi.org/10.1097/CAD.0000000000000810
Ailawadhi, Sikander ; Sher, Taimur ; Azzouqa, Abdel Ghani ; Meghji, Zahara ; Jain, Tania ; Jani, Prachi ; Ahmed, Salman ; Diehl, Nancy ; Roy, Vivek ; Shah, Vishal ; Hodge, David ; Ailawadhi, Meghna ; Alegria, Victoria R. ; Paulus, Aneel ; Chanan-Khan, Asher ; Fonseca, Rafael. / Monoclonal antibody utilization characteristics in patients with multiple myeloma. In: Anti-cancer drugs. 2019 ; Vol. 30, No. 8. pp. 859-865.
@article{f9a331cba63a4b05931e2c0bc95bb663,
title = "Monoclonal antibody utilization characteristics in patients with multiple myeloma",
abstract = "This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78) were more heavily pre-treated than that in published clinical trials, whereas the elotuzumab patient (n = 13) profile was similar to that published before. Infusion time was on average 2 hours less than the prescribing guidelines and premedication use varied noticeably after the initial monoclonal antibody infusion, with an overall decrease over time. We noted higher than reported haematologic adverse events, especially neutropenia and fewer non-haematologic adverse events. 91.7{\%} infusion-related reactions were observed during the first monoclonal antibody infusion, with a subsequent decrease. All infusion-related reactions were grade 2 or less, and none of the patients discontinued treatment due to infusion-related reactions. Baseline allergy profile or laboratory tests were not associated with the likelihood of developing monoclonal antibody-related infusion-related reactions. The real-world safety profile of monoclonal antibodies showed varying adverse event patterns than those reported in previous clinical trials. The infusion-related reaction patterns were similar to previous reports. Despite changes in premedication regimens safety was maintained in succeeding infusions. Such treatment utilization data is vital to broaden our knowledge of approved therapeutic agents and maximize their benefits for patients.",
author = "Sikander Ailawadhi and Taimur Sher and Azzouqa, {Abdel Ghani} and Zahara Meghji and Tania Jain and Prachi Jani and Salman Ahmed and Nancy Diehl and Vivek Roy and Vishal Shah and David Hodge and Meghna Ailawadhi and Alegria, {Victoria R.} and Aneel Paulus and Asher Chanan-Khan and Rafael Fonseca",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/CAD.0000000000000810",
language = "English (US)",
volume = "30",
pages = "859--865",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Monoclonal antibody utilization characteristics in patients with multiple myeloma

AU - Ailawadhi, Sikander

AU - Sher, Taimur

AU - Azzouqa, Abdel Ghani

AU - Meghji, Zahara

AU - Jain, Tania

AU - Jani, Prachi

AU - Ahmed, Salman

AU - Diehl, Nancy

AU - Roy, Vivek

AU - Shah, Vishal

AU - Hodge, David

AU - Ailawadhi, Meghna

AU - Alegria, Victoria R.

AU - Paulus, Aneel

AU - Chanan-Khan, Asher

AU - Fonseca, Rafael

PY - 2019/9/1

Y1 - 2019/9/1

N2 - This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78) were more heavily pre-treated than that in published clinical trials, whereas the elotuzumab patient (n = 13) profile was similar to that published before. Infusion time was on average 2 hours less than the prescribing guidelines and premedication use varied noticeably after the initial monoclonal antibody infusion, with an overall decrease over time. We noted higher than reported haematologic adverse events, especially neutropenia and fewer non-haematologic adverse events. 91.7% infusion-related reactions were observed during the first monoclonal antibody infusion, with a subsequent decrease. All infusion-related reactions were grade 2 or less, and none of the patients discontinued treatment due to infusion-related reactions. Baseline allergy profile or laboratory tests were not associated with the likelihood of developing monoclonal antibody-related infusion-related reactions. The real-world safety profile of monoclonal antibodies showed varying adverse event patterns than those reported in previous clinical trials. The infusion-related reaction patterns were similar to previous reports. Despite changes in premedication regimens safety was maintained in succeeding infusions. Such treatment utilization data is vital to broaden our knowledge of approved therapeutic agents and maximize their benefits for patients.

AB - This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78) were more heavily pre-treated than that in published clinical trials, whereas the elotuzumab patient (n = 13) profile was similar to that published before. Infusion time was on average 2 hours less than the prescribing guidelines and premedication use varied noticeably after the initial monoclonal antibody infusion, with an overall decrease over time. We noted higher than reported haematologic adverse events, especially neutropenia and fewer non-haematologic adverse events. 91.7% infusion-related reactions were observed during the first monoclonal antibody infusion, with a subsequent decrease. All infusion-related reactions were grade 2 or less, and none of the patients discontinued treatment due to infusion-related reactions. Baseline allergy profile or laboratory tests were not associated with the likelihood of developing monoclonal antibody-related infusion-related reactions. The real-world safety profile of monoclonal antibodies showed varying adverse event patterns than those reported in previous clinical trials. The infusion-related reaction patterns were similar to previous reports. Despite changes in premedication regimens safety was maintained in succeeding infusions. Such treatment utilization data is vital to broaden our knowledge of approved therapeutic agents and maximize their benefits for patients.

UR - http://www.scopus.com/inward/record.url?scp=85071549776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071549776&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000810

DO - 10.1097/CAD.0000000000000810

M3 - Article

C2 - 31415286

AN - SCOPUS:85071549776

VL - 30

SP - 859

EP - 865

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -